EP0413700A1 - Neue alkylphosphono- und phosphoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel - Google Patents

Neue alkylphosphono- und phosphoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel

Info

Publication number
EP0413700A1
EP0413700A1 EP89904069A EP89904069A EP0413700A1 EP 0413700 A1 EP0413700 A1 EP 0413700A1 EP 89904069 A EP89904069 A EP 89904069A EP 89904069 A EP89904069 A EP 89904069A EP 0413700 A1 EP0413700 A1 EP 0413700A1
Authority
EP
European Patent Office
Prior art keywords
general formula
serine
radical
compounds
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP89904069A
Other languages
German (de)
English (en)
French (fr)
Inventor
Hans Brachwitz
Reinhild Schönfeld
Peter Langen
Friedrich Paltauf
Albin Hermetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hafslund Nycomed Pharma AG
Original Assignee
Hafslund Nycomed Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DD31486888A external-priority patent/DD299727A7/de
Priority claimed from DD31835988A external-priority patent/DD289892A7/de
Application filed by Hafslund Nycomed Pharma AG filed Critical Hafslund Nycomed Pharma AG
Publication of EP0413700A1 publication Critical patent/EP0413700A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • New alkylphosphono- and phosphoserines processes for their preparation and pharmaceutical compositions containing them
  • the invention relates to new alkyl phosphono- and phosphoserines, processes for their preparation and their use.
  • the invention relates to compounds of the general formula I of the formula sheet in which R is a straight-chain or branched saturated or unsaturated aliphatic hydrocarbon radical having 6 to 30 carbon atoms, which is optionally substituted by halogen, the radicals OR 1 , SR 1 , NR 1 R 2 can be, where R 1 and R 2 each represent a hydrogen atom or an alkyl or acyl radical having 1-6 C atoms, or a radical OR ', where R' is a straight-chain or branched saturated or unsaturated aliphatic hydrocarbon radical having 6-30 C atoms, which may optionally be substituted by the radicals OR 1 , SR 1 or NR 1 R 2 , where R 1 and R 2 have the meaning given above.
  • R denotes a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical having 6 to 30 carbon atoms, preferably having 10 to 25 carbon atoms.
  • examples of such radicals are decyl, dodecyl, tetradecyl, hexadecyl, octadexyl, arachyl, 17-methyl-n-octadecyl radicals or the cis-9-n-octadecenyl radical.
  • These radicals can also be substituted by halogen, for example by Cl, Br, F or by the radicals OR 1 , SR 1 , NR 1 R 2 .
  • R 1 and R 2 mean independently of one another hydrogen or an alkyl or acyl radical having 1 to 6 carbon atoms, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, pentyl, Hexyl radical or for example a formyl, acetyl, propionyl, butyryl, i-butyryl radical.
  • R can furthermore denote the radical OR ', where R' represents a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical having 6 to 30 C atoms, for example a decyl, dodecyl, tetradecyl, hexadecyl, octacedyl, 1, 7-methyl-n-octadecyl radicals or the cis-9-n-octadecenyl radical.
  • R' represents a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical having 6 to 30 C atoms, for example a decyl, dodecyl, tetradecyl, hexadecyl, octacedyl, 1, 7-methyl-n-octadecyl radicals or the cis-9-n-octadecenyl radical.
  • radicals can optionally be substituted by the radicals OR 1 , SR 1 , NR 1 R 2 , where R 1 and R 2 independently of one another are hydrogen or an alkyl or acyl radical having 1-6 C atoms.
  • the alkylphosphono- and -phosphoserines have certain structural relationships with physiologically active naturally occurring phospholipids, e.g. B. phosphatidylserines. However, they differ from these in that they contain no glycerol component. Compared to the naturally occurring phosphatidylserines, the alkylphospho-and -phospho ⁇ oserines according to the invention have higher biostability. They represent potential cytostatics and virustatics.
  • the new alkylphosphono- or -phosphoserines can be prepared by a) a compound of the general formula II of the formula sheet in which R has the meaning given above and A and B is a hydroxyl group or if R is OR 'A is also halogen , preferably Cl and Br, and B may also be halogen, preferably Cl and Br, an alkoxy or aryloxy radical or, if appropriate, the salts of these compounds with a serine derivative of the general formula III of the formula sheet in which X is benzyl, t-butyl, phthalimidomethyl, isopropyl , Benzhydryl or another protective group which can be removed in the usual way,
  • Y is N-benzoyloxycarbonyl, Nt-butoxycarbonyl, N-phthaloyl or another protective group which can be split off in the usual way, optionally in the presence of a condensing agent to give compounds of the general Formula IV of the formula sheet is implemented, the protective groups are split off and the product is optionally converted into a salt or
  • C and D independently of one another are H or methyl and E is methyl and n is 2-6, in the presence of phospholipase D is reacted with L-serine.
  • the compounds of the general formula II of the formula sheet used as starting compounds can be prepared in a manner known per se by first synthesizing the dimethyl alkylphosphonate from the corresponding alkyl bromide R-Br and trimethyl phosphite, this by reaction with a mixture of trimethylsilyl chloride and sodium iodide in the trimethylsilyl ester transferred and hydrolyzed by exposure to water.
  • R is the radical OR '
  • phosphoric acid esters, phosphoric acid dihalides or phosphoric acid ester halides are used as starting compounds.
  • the corresponding phosphoric acid dichlorides can be obtained in a manner known per se by reacting alkyl alcohols with phosphorus oxychloride.
  • the compounds of the general formula II are generally reacted by converting the compounds into the salt of a base, for example pyridine, and then reacting this salt with the serine derivative.
  • the reaction is preferably carried out in the presence of a condensing agent, for example in the presence of 2,4,6-triisopropylbenzenesulfochloride under anhydrous conditions and preferably in the presence of an inert organic solvent.
  • a condensing agent for example in the presence of 2,4,6-triisopropylbenzenesulfochloride under anhydrous conditions and preferably in the presence of an inert organic solvent.
  • Pyridine is an example of a solvent.
  • the reactants are usually used in an equimolar amount, but it is also possible to use an up to four molar excess of serine derivative.
  • the reaction takes place at temperatures of about 5-60 ° C., preferably at room temperature.
  • the acid chloride still present is destroyed in the customary manner, for example by adding water in the reaction solution, and the product is isolated in the customary manner, for example by extraction with diethyl ether.
  • the compounds of the general formula IV of the formula sheet obtained in this way can be further purified before the protective groups are split off, for example by column chromatography on silica gel.
  • the protective groups are split off in a customary manner, for example by catalytic hydrogenolysis, hydrazinolysis, treatment with HCl or formic acid, preferably in an inert solvent.
  • the compounds of the general formula I of the formula sheet can then be isolated in a known manner and optionally further purified, for example by chromatography.
  • alkylphosphono- and -phosphoserines according to the invention can also be prepared enzymatically.
  • compounds of the general formula V of the formula sheet are reacted with LSerin in the presence of phospholipase D.
  • a solution or suspension of the compounds of the general formula V of the formula sheet with an excess of L-serine in an aqueous buffer system for example in an acetate or tris buffer solution at pH values of about 4-8.5, preferably 5-6, particularly preferably 5.6, in the presence of about 0.01-0.1 M and in the presence of phospholipase D with the addition of diethyl ether or a mixture of diethyl ether with another organic solvent, for example chloroform.
  • the reaction takes place at temperatures of about 5-60 ° C, preferably 35-45 ° C. During the reaction, the reaction mixture is stirred vigorously or shaken.
  • the reaction time is about 0.5-48 hours.
  • the enzyme phospholipase D is, for example, by adding a 0.1 M EDTA Solution deactivated and the compounds of general formula I of the formula sheet isolated in the usual way.
  • the new alkylphosphono- or -phosphoserines have a strong cytostatic and virustatic effect. To determine the cytostatic effect, the antiproliferative effect on Ehrlich ascites tumor cells was examined. It was found that the compounds according to the invention have excellent cytostatic activity.
  • the compounds of the general formula I of the formula sheet are intended for use in humans and can be administered in a customary manner, for example orally or parenterally. They are preferably administered orally, the daily dose being about 0.05 to 20 mg / kg of body weight, preferably 0.05 to 5 mg / kg of body weight.
  • the attending doctor can prescribe lower or higher doses outside this range.
  • the compounds of the formula I of the formula sheet can be administered alone or in conjunction with other pharmaceutically active substances, the content of the compounds of the general formula I of the formula sheet being between 0.1 and 99%.
  • the pharmaceutically active compounds are in a mixture with suitable inert auxiliaries and / or carriers or diluents, for.
  • suitable inert auxiliaries and / or carriers or diluents for.
  • the pharmaceutical preparations can be in solid form, for example as tablets, coated tablets, suppositories, capsules and the like.
  • semisolid form for example as ointments or in liquid form, for example as suspensions or emulsions. Otherwise they are sterilized and contain auxiliaries such as preservatives, stabilizers and emulsifiers, salt for changing the osmotic Druck u.
  • auxiliaries such as preservatives, stabilizers and emulsifiers, salt for changing the osmotic Druck u.
  • pharmaceutical preparations can contain the compounds according to the invention in combination with other therapeutically valuable substances.
  • the compounds according to the invention can be formulated, for example, together with the abovementioned auxiliaries and / or carriers or diluents to give combination preparations.
  • the residue obtained is extracted with 20 ml of diethyl ether and washed 3 ⁇ with 4 ml of diethyl ether.
  • the ethereal solutions are combined and concentrated in vacuo.
  • the residue is dissolved in chloroform and purified by column chromatography on 36 g of silica gel 60 (particle size 0.04-0.063 mm, 230-400 mesh, Merck).
  • the chloroform used for column chromatography is saturated with 25% aqueous ammonia.
  • Elution is carried out with 300 ml chloroform, 250 ml chloroform / methanol, 98: 2, v / v, 200 ml chloroform / methanol, 95: 5, v / v, 500 ml chloroform / methanol, 90: 10, v / v, 400 ml chloroform / methanol, 80:20, v / v.
  • the fraction size is 22 ml.
  • n-hexadecylphospho-L-serine (diammonium salt) obtained is uniform by thin layer chromatography.
  • the visualization takes place with molybdate reagent as well as with ninhydrin spray.
  • the substance (30.8 mg) is chromatographed on 2 g of silica gel 60 (particle size 0.04-0.063 mm, 230-400 mesh, Merck). The column is equilibrated with chloroform / methanol / aqueous 25% ammonia, 80: 20: 0.5, v / v / v. The substance is dissolved in the same mixture and added to the column.
  • Elution is carried out with 20 ml of chloroform / methanol 25% aqueous ammonia, 80: 20: 0.5 v / v / v, 20 ml of chloroform / methanol / 25% aqueous ammonia, 75: 25: 0.5, v / v / V, 20 ml chloroform / methanol / 25% aqueous ammonia, 70: 30: 0.5, V / V / V, 20 ml chloroform / methanol / 25% aqueous ammonia, 65: 35: 0.5, V / V / V, 260 ml chloroform / methanol / 25% aqueous ammonia, 60: 40: 0.5, V / V / V.
  • the compound is obtained from fraction 7-13 (fraction size 20 ml) by concentration.
  • the two solutions are mixed and 581 mg (1.92 mmol) of triisopropylbenzenesulfochloride are added to the mixture, the reaction mixture is stirred under anhydrous conditions at room temperature for 24 hours, after which the mixture is concentrated in vacuo, redistilled with toluene and the residue is dried over phosphorus pentoxide in vacuo is then extracted with 15 ml of diethyl ether and washed three times with 4 ml of diethyl ether, the ether solutions are combined and concentrated in vacuo, and 118 mg of the n-hexadecylphosphonoserine derivative IV are obtained from the residue obtained by recrystallization from acetonitrile Column chromatography on 8 g of silica gel 60 (particle size 0.04-0.063 mm, 230-400 mesh, Merck) ended chloroform and the solvent mixtures for the eluent contain 0.5% aqueous 25% ammonia.
  • the reaction mixture is then concentrated in vacuo and the residue is mixed with a mixture of 10 ml of chloroform / methanol, 2: 1, v / v, 1 ml of water and 0.02 ml of 25% aqueous ammonia, shaken and, after phase separation, the resulting organic Phase separated.
  • the aqueous phase is extracted three times with 5 ml of chloroform / methanol / water, 2: 1: 0.18, v / v / v, the organic solutions are combined and concentrated in vacuo.
  • To remove residual water repeated distillation with 1 ml of benzene / ethanol, 2: 3, V / V.
  • the product obtained, hexadecylphosphono-L-serine I is dried over phosphorus pentoxide in vacuo and then washed with acetone.
  • the substance is chromatographed on 2.2 g of silica gel 60 (particle size 0.04-0.063 mm, 230-400 mesh, Merck). The column is washed with chloroform / methanol / aqueous 25% ammonia, 80:20. 0.5, V / V / V equilibrated.
  • Elution is carried out with 20 ml of chloroform / methanol / aqueous 25% ammonia, 80: 20: 0.5, v / v / v, 20 ml of chloroform / methanol / aqueous 25% ammonia, 75: 25: 0.5, v / V / V, 20 ml chloroform / methanol / aqueous 25% ammonia, 70: 30: 0.5, V / V / V, 20 ml chloroform / methanol / aqueous 25% ammonia, 65: 35: 0.5 , V / V / V, 200 ml chloroform / methanol / aqueous 25% ammonia, 60: 40: 0.5, V / V / V.
  • the visualization takes place with molybdate reagent and with ninhydrin reagent.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP89904069A 1988-04-19 1989-04-13 Neue alkylphosphono- und phosphoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel Pending EP0413700A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DD314868 1988-04-19
DD31486888A DD299727A7 (de) 1988-04-19 1988-04-19 Alkyl- und alkenylphospho-l-serine, verfahren zu ihrer herstellung und verwendung
DD318359 1988-07-27
DD31835988A DD289892A7 (de) 1988-07-27 1988-07-27 Verfahren zur herstellung von alkylphosphonserinen

Publications (1)

Publication Number Publication Date
EP0413700A1 true EP0413700A1 (de) 1991-02-27

Family

ID=25748200

Family Applications (2)

Application Number Title Priority Date Filing Date
EP89904069A Pending EP0413700A1 (de) 1988-04-19 1989-04-13 Neue alkylphosphono- und phosphoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
EP89106544A Expired - Lifetime EP0338407B1 (de) 1988-04-19 1989-04-13 Neue Alkylphosphonoserine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP89106544A Expired - Lifetime EP0338407B1 (de) 1988-04-19 1989-04-13 Neue Alkylphosphonoserine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel

Country Status (11)

Country Link
US (1) US5155099A (enrdf_load_stackoverflow)
EP (2) EP0413700A1 (enrdf_load_stackoverflow)
JP (1) JPH03504965A (enrdf_load_stackoverflow)
DE (1) DE58904595D1 (enrdf_load_stackoverflow)
DK (1) DK167810B1 (enrdf_load_stackoverflow)
ES (1) ES2056998T3 (enrdf_load_stackoverflow)
FI (1) FI91966C (enrdf_load_stackoverflow)
GR (1) GR3008598T3 (enrdf_load_stackoverflow)
HU (1) HU204278B (enrdf_load_stackoverflow)
NO (1) NO177712C (enrdf_load_stackoverflow)
WO (1) WO1989010370A1 (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5117034A (en) * 1989-10-24 1992-05-26 Fuji Photo Film Co., Ltd. Phosphatidylserine derivatives
US5506217A (en) * 1991-04-25 1996-04-09 The University Of British Columbia Phosphonates as anti-cancer agents
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
EP0581793A1 (en) * 1991-04-25 1994-02-09 University Of British Columbia Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
DE4229877C2 (de) * 1992-09-04 1994-09-15 Max Delbrueck Centrum Phospho- bzw. Phosphono-(N-acyl)-serine und ihre Herstellung
US20040265927A1 (en) * 2001-09-18 2004-12-30 Bolton Anthony E. Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US6878532B1 (en) 2003-04-28 2005-04-12 Sioux Biochemical, Inc. Method of producing phosphatidylserine
EP1963343A1 (en) * 2005-12-14 2008-09-03 Novo Nordisk A/S Polypeptide protracting tags

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916249A (en) * 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
DD238979A1 (de) * 1985-07-03 1986-09-10 Akad Wissenschaften Ddr Verfahren zur herstellung von o-alkylglycerophosphoserin-analogen
DD239405A1 (de) * 1985-07-15 1986-09-24 Akad Wissenschaften Ddr Verfahren zur herstellung von trifluoralkyl-glycerophospho-l-serinen
DD238978A1 (de) * 1985-07-03 1986-09-10 Akad Wissenschaften Ddr Verfahren zur herstellung von 2-o-alkyl-i-des oxy-1-halogenglycero-3-phospho-l-serinen
JPH064651B2 (ja) * 1985-11-27 1994-01-19 花王株式会社 リン酸エステルおよびその製造方法
US4751320A (en) * 1985-11-27 1988-06-14 Kao Corporation Phosphoric ester and process for producing same
DE3606633A1 (de) * 1986-02-28 1987-09-03 Max Planck Gesellschaft Neue phosphoverbindungen und diese enthaltende arzneimittel
JPH0761276B2 (ja) * 1986-11-14 1995-07-05 名糖産業株式会社 酵素法リン脂質−ｄ−セリン誘導体の製造法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8910370A1 *

Also Published As

Publication number Publication date
HUT51632A (en) 1990-05-28
ES2056998T3 (es) 1994-10-16
FI91966B (fi) 1994-05-31
FI905051A0 (fi) 1990-10-15
EP0338407A1 (de) 1989-10-25
NO904416L (no) 1990-10-12
EP0338407B1 (de) 1993-06-09
US5155099A (en) 1992-10-13
NO904416D0 (no) 1990-10-12
NO177712C (no) 1995-11-08
DK250090D0 (da) 1990-10-17
DK167810B1 (da) 1993-12-20
DE58904595D1 (de) 1993-07-15
WO1989010370A1 (en) 1989-11-02
NO177712B (no) 1995-07-31
FI91966C (fi) 1994-09-12
HU204278B (en) 1991-12-30
JPH03504965A (ja) 1991-10-31
GR3008598T3 (enrdf_load_stackoverflow) 1993-10-29
DK250090A (da) 1990-10-17

Similar Documents

Publication Publication Date Title
EP0252505B1 (de) 1-Hydroxy-3-(N-methyl-N-propylamino)propan-1,1-diphosphonsäure; Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
DE68904104T2 (de) Phenol-substituierte gem-diphosphonat-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
EP0312087B1 (de) Bis-aldonsäureamide und Verfahren zu ihrer Herstellung
DE3248900C2 (enrdf_load_stackoverflow)
WO1987003478A2 (en) Medicaments
DE2414680C2 (de) Substituierte 2-Furancarbonsäuren und 2-Furancarbonsäureester, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
EP0036583B1 (de) Glycerin-3-phosphorsäurehalogenalkylester und Verfahren zu ihrer Herstellung und Weiterverarbeitung
EP0338407B1 (de) Neue Alkylphosphonoserine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
DE69230532T2 (de) Inositolderivate, sie enthaltende präparate und ihre herstellung
EP0099068B1 (de) Neue Glycerinderivate zur Synthese von Phospholipiden
EP0002062B1 (de) Phosphororganische Ringverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0229128B1 (de) Glycero-3(2)-phospho-l-serinderivate und diese enthaltende pharmazeutischen präparate
EP0021391B1 (de) Phosphonoameisensäurehydrazide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
EP1521761B1 (de) Cdg-therapie mit mannose
EP0300960A2 (de) Neue pharmazeutische Präparate sowie neue Lactosylverbindungen und ihre Herstellung
DE4030587A1 (de) Verfahren zur herstellung von d-myoinosit-1-phosphat
EP0432183B1 (de) Neue cytidin-5'-diphosphatalkanole und- glycerole, ein verfahren zu deren herstellung, sowie deren verwendung
DE2621576A1 (de) 3,5-bisoxydierte-2-(omega-halogen- 3-oxydierte-1-alkenyl)-cyclopentan-1- oenanthsaeuren und deren derivate, die herstellung dieser verbindungen sowie diese verbindungen enthaltende praeparate
DE2345695A1 (de) Verfahren zur herstellung neuer analoga bekannter prostaglandine
AT393505B (de) Arzneimittel, welche alkylphosphoamine in kombination mit einem alkylglycerin enthalten
DE2459985B2 (de) Phosphorsäureester des Cholestanols und des Epicholestanols und deren Salze, Verfahren zur Herstellung derselben und antiphlogistische Mittel mit einem Gehalt derselben
DE3304870A1 (de) Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DD299727A7 (de) Alkyl- und alkenylphospho-l-serine, verfahren zu ihrer herstellung und verwendung
DD289892A7 (de) Verfahren zur herstellung von alkylphosphonserinen
EP0259752A2 (de) Sacchharid-Phosphate und ihre Ester und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19901005

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 89106544.3/0338407 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 14.07.92.